Interpace Biosciences Incorporation announced the financial results for the second quarter that ended on June 30, 2022. The Company also provides business and financial updates. It also announced the new clinical validation data for the thyroid and cancer test platform.
It was published online within thyroid as the leading peer-reviewed journal for original research on thyroid cancer. Moreover, the new data demonstrated the addition of microRNA pairwise expression profiling that is provided clinically and statistically superior risk stratification of indeterminate thyroid nodules.
Besides that, the algorithmic classification analysis provides the original ThraMIR assay. In addition, the Company will launch the point 2 glucose with a new pancreatic cyst fluid tumor. It makes the diagnostic test offering require a common cyst fluid volume (0.2ml).
Moreover, intracystic glucose is considered to be more accurate compared to diagnostic standards. It also includes the carcinoembryonic antigen with the specifications to use in the pancreatic cyst fluid, and it has been shown to be able to provide an accurate result even with viscous or bloody samples.
The Chief scientific officer at Interpace Biosciences explained that the medical analysis might also reduce the risk of RNA sampling error as the miRNA can migrate throughout the thyroid nodule. As a result, they may be less affected by spatial variability than the distribution of cells with DNA mutations.
About Interpace Biosciences:
Interpace Biosciences is an emerging leader in personalized medicine and offers specialized services along the therapeutic value chain, from early diagnosis and prognostic planning to targeted therapeutic applications.
Besides offering the common stock under the name IDXG Stock, the Company provides specialized services along the therapeutic value chain, including early diagnosis and prognostic planning.
The multiple clinical services throughout the Interpace diagnostic provides the clinical use of the molecular diagnostic test, bioinformatics and pathology services for evaluation of the factor of risk and cancer.
Moreover, the clinical services through Interpace provide clinically used molecular diagnostic tests with bioinformatics and pathology. It also evaluates cancer risk by leveraging the latest technology in personalized medicine for improved patient diagnosis and management.
It also leverages the latest technology in personalizing the patients and their management. The Company is utilizing the next-generation sequencing assay to diagnose thyroid cancer from the thyroid nodules. It also has a proprietary gene expression assay and much more.
About IDXG Stock:
A financial statement analysis of IDXG Stock indicates that the short-term assets of this Company cover the short-term liabilities. On the other hand, this Company’s long-term investments are also exceeding and covering the long-term liabilities. Moreover, the IDXG Stock holds the current price of 2.05 US dollars on September 21, 2022.
The other pharma services also advance personalized medicine by parenting with pharmaceuticals, academics, and technology leaders to effectively integrate into the drug development and clinical trial programs to deliver safer and more effective improving patient care.
